NewsBusiness Next frontier in anti-obesity drugs: oral GLP-1s with OTC switch September 26, 2024 0 Facebook Twitter Pinterest WhatsApp ReddIt Nalin Prutimongkol/iStock via Getty Images The race to develop oral obesity drugs is heating up. Eli Lilly (LLY) and Novo Nordisk (NVO), makers of the highly popular injectable GLP-1 class of weight loss drugs, as well as potential new entrants Pfizer ( UBS lifts Softbank stock target, maintains buy By Investing.comDateJune 22, 2024In relation toBusinessChina’s Sinopec posts 2.6% rise in first-half profit By ReutersDateAugust 25, 2024In relation toBusinessOppenheimer starts Vaxart at outperform, cites oral vaccine focus (NASDAQ:VXRT)DateAugust 16, 2024In relation toBusiness
